July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Combined nonsense mediated decay inhibition and suppression as a treatment approach for choroideremia
Author Affiliations & Notes
  • Mohamed Ali
    UCL Institute of Ophthalmology, London, United Kingdom
  • Dhani Tracey-White
    UCL Institute of Ophthalmology, London, United Kingdom
  • Matthew Smart
    UCL Institute of Ophthalmology, London, United Kingdom
  • Mariya Moosajee
    UCL Institute of Ophthalmology, London, United Kingdom
    Moorfields Eye Hospital , London, United Kingdom
  • Footnotes
    Commercial Relationships   Mohamed Ali, None; Dhani Tracey-White, None; Matthew Smart, None; Mariya Moosajee, None
  • Footnotes
    Support  Choroideremia Research Foundation, Fight for Sight UK, NIHR and Wellcome Trust
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5314. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohamed Ali, Dhani Tracey-White, Matthew Smart, Mariya Moosajee; Combined nonsense mediated decay inhibition and suppression as a treatment approach for choroideremia. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5314.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Nonsense-mediated decay (NMD) is a cellular surveillance mechanism which degrades nonsense-containing mRNA. This occurs at differing rates depending on a variety of factors including the position of the mutation. Therapies based on nonsense suppression require mRNA as the substrate for drug efficacy, hence inhibiting NMD may have the potential to improve translational readthrough with subsequent production of functional protein. Aim: To test amlexanox, an anti-inflammatory drug with dual NMD inhibition and nonsense suppression, for its ability to restore functional rab escort protein 1 (REP1) in two choroideremia (CHM) patient fibroblast cell lines.

Methods : Skin biopsies were taken from two affected male CHM patients with p.Tyr42* (Exon 3 UAG stop) and p.Arg270* (Exon 6 UGA stop) nonsense mutations. Dermal fibroblast cell lines were established and baseline qRT-PCR was undertaken to measure mRNA levels as an indicator of NMD activity. Dose-response experiments were conducted to determine the safest and most efficacious dose of amlexanox. A single dose of 300 µM was administered to fibroblasts, 24 hours post-treatment, qRT-PCR was repeated with functional prenylation assays (n=3 independent experiments, all values are mean±SEM).

Results : CHM p.Tyr42* and p.Arg270* fibroblasts showed mean 83±2% and 18±1% baseline mRNA levels, respectively. Amlexanox-treated p.Tyr42* and p.Arg270* cell lines showed increases to 96±1% and 73±5% mRNA levels post-treatment suggesting NMD inhibition, particularly in the latter. Functional prenylation assay showed 100% accumulation of unprenylated rabs in both untreated CHM fibroblasts, but a significant mean (±SEM) reduction of 39±4% for p.Tyr42*, and 26±5% for p.Arg270*, following treatment with amlexanox.

Conclusions : The CHM p.Tyr42* fibroblasts had a higher baseline level of mRNA with less unprenylated rab accumulation post-treatment, indicating baseline mRNA may be a prognostic indicator for treatment response in future clinical trials. The p.Arg270* mRNA levels were boosted through amlexanox treatment enabling effective readthrough. Drugs with either combined NMD inhibition and nonsense suppression, or complementary actions may be the best approach for providing personalised medicine for treating nonsense-mediated choroideremia and other related inherited retinal dystrophies.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.